Pharma sector stocks today, September 15: Alembic Pharma jumps 1.58%, Strides Pharma up 0.93%; Divi’s Laboratories falls 1.21%
NiveshIQ
NSE: APLLTD · Pharma
Alembic Pharmaceuticals Ltd.
₹810.95▼ ₹5.45 (-0.67%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on APLLTD. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Limited is an integrated pharmaceutical company that develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company's products are categorized across various therapeutic areas, including cardiology, orthopaedics, and anti-diabetic. Its revenue drivers include generics formulations in oral solids, oncology oral solids and injectables, general injectables, and ophthalmic products. Notably, the company has reported a 25.02% year-over-year increase in standalone net sales for June 2026, reaching Rs 1,868.06 crore. Additionally, Alembic Pharma's consolidated net sales for June 2026 rose 25.66% year-over-year to Rs 2,149.77 crore. The company's Q1 FY27 revenue jumped 26% to ₹2,150 Crore, with US sales surging 49%. Alembic Phar
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹6,229 Cr +10.20% | ₹6,673 Cr +7.10% | ₹7,345 Cr +10.10% |
| EBITDA Margin | 14.98% | 15.09% | 15.97% |
| Net Profit | ₹616.00 Cr +80.10% | ₹583.00 Cr -5.40% | ₹670.83 Cr +15.10% |
| EPS | ₹31.34 | ₹29.67 | ₹34.33 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Alembic Pharma: USFDA சோதனையில் அசத்தல் வெற்றி! வதோதரா ஆலையில் 'ஜீரோ' குறைபாடுகள்
Alembic Pharma Clears Vadodara USFDA Audit With Zero Observations
🔒
+ 3 more stories about Alembic Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 150 Cr, PAT ₹172 Cr, EPS ₹8.80, EBITDA margin 16.1%. Growth context: revenue QoQ +16.3%, PAT QoQ -14.5%.
Management commentary highlights the importance of product launches, approvals, and therapy-mix improvement as key drive...
FY26 (last completed FY): revenue ₹7, 345 Cr, PAT ₹671 Cr, EBITDA margin 16.0%, EPS ₹34.33. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for APLLTD
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track APLLTD alongside your other holdings
Unlock full APLLTD research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alembic Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Alembic Pharmaceuticals Ltd. (APLLTD) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alembic Pharmaceuticals Ltd.?
Alembic Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹1,598,942.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.